G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Salvage Therapy for Refractory or Relapsed Acute Lymphocytic Leukemia
TL;DR: The overall prognosis for patients with relapsed or refractory adult ALL remains poor, and further insight into the biology of ALL is required, and novel therapeutic agents are needed to counter mechanisms of resistance.
Journal ArticleDOI
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Guillermo Montalban-Bravo,Rashmi Kanagal-Shamanna,Christopher B. Benton,Caleb A. Class,Kelly S. Chien,Koji Sasaki,Kiran Naqvi,Yesid Alvarado,Tapan M. Kadia,Farhad Ravandi,Naval Daver,Koichi Takahashi,Elias Jabbour,Gautham Borthakur,Naveen Pemmaraju,Marina Konopleva,Kelly A. Soltysiak,Sherry Pierce,Carlos E. Bueso-Ramos,Keyur P. Patel,Hagop M. Kantarjian,Guillermo Garcia-Manero +21 more
TL;DR: Outcomes of patients with TP53-mutated MDS are heterogeneous and that transformation may be driven not only by TP53 but also by other factors, according to a multivariable model for overall survival that included revised International Prognostic Scoring System categories and TP53 VAF.
Journal ArticleDOI
A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Naveen Pemmaraju,Hagop M. Kantarjian,Tapan M. Kadia,Jorge E. Cortes,Gautam Borthakur,Kate J. Newberry,Guillermo Garcia-Manero,Farhad Ravandi,Elias Jabbour,Sara Dellasala,Sherry Pierce,Srdan Verstovsek +11 more
TL;DR: In this cohort of heavily pretreated patients with relapsed or refractory acute leukemias, ruxolitinib was overall reasonably well tolerated, with 1 patient achieving CRp.
Journal ArticleDOI
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Yasuhiro Oki,Hagop M. Kantarjian,Xian Zhou,Jorge E. Cortes,Stefan Faderl,Srdan Verstovsek,Susan O'Brien,Charles Koller,Miloslav Beran,B. Nebiyou Bekele,Sherry Pierce,Deborah A. Thomas,Farhad Ravandi,William G. Wierda,Francis J. Giles,Alessandra Ferrajoli,Elias Jabbour,Michael J. Keating,Carlos E. Bueso-Ramos,Elihu H. Estey,Guillermo Garcia-Manero +20 more
TL;DR: The results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease.
Journal ArticleDOI
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival
Gautam Borthakur,Hagop M. Kantarjian,Xuemei Wang,William Plunkett,Varsha Gandhi,Stefan Faderl,Guillermo Garcia-Manero,Farhad Ravandi,Sherry Pierce,Elihu H. Estey +9 more
TL;DR: In vitro and ex vivo observations suggest that increases in intracellular ara‐C levels influenced by administration of fludarabine and granulocyte colony‐stimulating factor increase the effect of ara-C, prompting us to clinically evaluate the efficacy of such combinations.